0001209191-18-045576.txt : 20180806
0001209191-18-045576.hdr.sgml : 20180806
20180806172148
ACCESSION NUMBER: 0001209191-18-045576
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180802
FILED AS OF DATE: 20180806
DATE AS OF CHANGE: 20180806
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 18995627
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-02
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP\Chief Commercial Officer
Common Stock
2018-08-02
4
M
0
2125
131.89
A
48877
D
Common Stock
2018-08-02
4
S
0
2125
179.00
D
46752
D
Common Stock
2018-08-02
4
M
0
2155
91.05
A
48907
D
Common Stock
2018-08-02
4
S
0
2155
174.59
D
46752
D
Common Stock
2018-08-03
4
M
0
4250
109.14
A
51002
D
Common Stock
2018-08-03
4
M
0
1553
86.52
A
52555
D
Common Stock
2018-08-03
4
S
0
5803
174.20
D
46752
D
Common Stock
140
I
401(k)
Stock Option (Right to Buy)
131.89
2018-08-02
4
M
0
2125
0.00
D
2025-07-20
Common Stock
2125
8500
D
Stock Option (Right to Buy)
91.05
2018-08-02
4
M
0
2155
0.00
D
2026-02-01
Common Stock
2155
12931
D
Stock Option (Right to Buy)
109.14
2018-08-03
4
M
0
4250
0.00
D
2025-02-02
Common Stock
4250
8500
D
Stock Option (Right to Buy)
86.52
2018-08-03
4
M
0
1553
0.00
D
2027-02-02
Common Stock
1553
15533
D
Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
The option vests in 16 quarterly installments from 7/21/2015.
The option vests in 16 quarterly installments from 2/2/2016.
The option vests in 16 quarterly installments from 2/3/2015.
The option vests in 16 quarterly installments from 2/3/2017.
/s/ Stephen Migausky, Attorney-in-Fact
2018-08-06